Information Provided By:
Fly News Breaks for January 31, 2020
EW
Jan 31, 2020 | 05:19 EDT
Piper Sandler analyst Adam Maeder raised his price target for Edwards Lifesciences to $270 from $262 and reiterates an Overweight rating on the shares. The company reported Q4 results that beat consensus estimates on the top-line behind "robust" TAVR growth, but missed slightly on adjusted earnings due to one-time costs associated with changes to Cardioband manufacturing and accelerated spending to drive TAVR therapy awareness, Maeder tells investors in a research note. The analyst sees room for potential upside to the company's 2020 guidance behind strength in TAVR.